Pfizer share price today

Pfizer Ltd's share price was ₹3,856.90 at the close on 5 November 2026. It has been falling for 43 weeks. That is 14.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹3,612 and ₹5,098, and at that close it sat 16% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Pfizer Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 9 weeks running.

Over the last 11 years the share price moved +100% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 6 quarters in a row, highest quarterly revenue in 15 quarters and operating margin up 3 points on a year earlier.

1. Revenue up on a year earlier for 6 quarters in a row

   In the June 2026 quarter revenue was ₹653 crore, +8.3% on a year earlier.

2. Highest quarterly revenue in 15 quarters

   Revenue of ₹653 crore in the June 2026 quarter is the highest of the last 15 quarters.

3. Operating margin up 3 points on a year earlier

   38% in the June 2026 quarter, from 35%.

For July to September 2026 (the quarter ended 30 September 2026), Pfizer reported revenue of ₹727 crore, up 13.2% from ₹642 crore a year earlier, and a profit of ₹313 crore, up 65.6% from ₹189 crore.

Pfizer results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Pfizer closed at ₹3,856.90 on 5 November 2026, down 24.0% from ₹5,075.00 a year earlier (7 November 2025) and down 23.0% over five years. Its highest weekly close since March 2016 was ₹6,164.20 on 6 September 2024.

Pfizer share price: then and now

Weekly closing prices. Each change is the move from that price to the 5 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 5 November 2026.

5 Nov 2026: Pfizer closed at ₹3,856.90, up 4.6% on the week and up 1.3% on the month. Results for July to September 2026: Revenue up 13.2% and profit up 65.6% on a year earlier.

Earlier

• 17 Jul 2026: ex-date for a dividend of ₹75 a share.

Pfizer paid ₹75 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.94% at the ₹3,856.90 close on 5 November 2026. The last was a dividend of ₹75 a share, ex-date 17 July 2026.

Pfizer dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Pfizer Ltd paid out 48% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Pfizer is on 4 of our India lists: 52 week high & low, Dividend stocks, Small & mid cap stocks and Pharma stocks.

Pfizer Ltd earned ₹313 Cr of net profit in the Sep 2026 quarter, +65.6% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹722 Cr. Over 10 years profit has grown 9.0% a year on average. That is 43.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹189 Cr.

For the full year, FY26 profit was ₹722 Cr (−6.0% on the year before).

Why profit moved: revenue changed +13.2% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +10.8% and revenue +11.9%. Profit and revenue are moving at about the same pace.

Pfizer Ltd reported ₹727 Cr of revenue in the Sep 2026 quarter, +13.2% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 10 years it has grown 2.3% a year on average. The last full year, FY26, came in at ₹2,520 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,654 Cr.

FY26 revenue was ₹2,520 Cr, +10.5% on the year before.

Recent pace: the last four quarters grew +11.9% on average, against 2.3% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.7%, against +8.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +2.3%, against +17.9% a year (rolling over).

Pfizer Ltd's operating margin was 36.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 18.0% and 36.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.1 percentage points on the year while gross margin changed −5.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 92% of Pfizer Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹968 Cr of operating cash against ₹722 Cr of profit. After ₹24.0 Cr of spending on assets, ₹944 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 92% of profit came in as cash: the cash cycle got 45 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Pfizer Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 132 days in FY26, up from 87 days in FY21. It spent ₹122 Cr on assets over the last 3 years. Customers take 26 days to pay, and stock sits for 195 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,520 Cr, each day of that cycle ties up about ₹6.9 Cr, so roughly ₹911 Cr is tied up in the business at any time.

FY26: customers took 26 days to pay and stock sat for 195 days, about 6.4 months of sales sitting as stock, for a full cycle of 132 days, longer than FY21's 87.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 195 days. Customers pay about 26 days after that. Suppliers are paid at 89 days. Together that makes the 132-day cycle.

Spending on assets: ₹122 Cr over the last 3 years, against ₹181 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹20.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Pfizer Ltd's P/E is 22.2×, about the lowest it has ever been. Its usual P/E (the middle reading) is 34.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹187.85.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.